RxDoctor Payments Data

Kenneth Choi, MD

Pain Medicine · Denison, TXNPI 1598055154

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $76,175 of the $105,741 with a category attached, or 72.0%. Boston Scientific accounts for 92.2% of it on its own, with 17 other manufacturers making up the rest. Among pain medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$105,741in general payments, 2019–2025

Across 253 payments — averaging $417.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$97K
  • Abbott$6K
  • Si-bone, Inc.$578
  • SPR Therapeutics, Inc$348
  • AbbVie$243
  • Medtronic$148
  • plus $482 from 12 others

What the payments were for

  • Consulting fees$12,88812%
  • Speaking & faculty fees$76,17572%
  • Travel & lodging$9,1829%
  • Food & beverage$7,4967%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,741 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$364,187
Medicare patients
489
Services billed
3,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine246$57,271
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,226$37,051
Pregabalin620$12,077
Gabapentin710$10,248
MovantikNaloxegol Oxalate22$8,829
LinzessLinaclotide13$7,065
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen257$6,964
BelbucaBuprenorphine Hcl13$5,566
Acetaminophen-CodeineAcetaminophen With Codeine213$4,488
Buprenorphine Hcl127$4,284
Tramadol Hcl332$2,874
Lidocaine33$2,429
Topiramate120$2,224
Oxycodone Hcl134$1,905
Lubiprostone26$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$243$7,06513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Denison

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →